Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Bullboard Posts
Post by Leafs4Lifeon Apr 09, 2018 6:19pm
227 Views
Post# 27855939

Revenue projection - a million bucks in 3 weeks or less

Revenue projection - a million bucks in 3 weeks or lessSince we don't know when CannaStrips will go into full production or show up in dispensaries (although, based on today's announcement I would be shocked if we don't hear something about it this week) I will focus on the Reveur product line exclusively for this bit of guesswork.

On March 8th LDS announced the Reveur product line. In the release they mentioned having already produced 15,000 grams of the "high end" product (in February). In speaking with IR they confirmed the company continued to produce Reveur through March so they undoubtedly have more product than that now. 

If you visit the Harbourside website and search for resins there are 5 products to choose from. Two are being sold at half price "while supplies last" (I assume these products are being sold at clearance prices because they will not satisfy the California quality guidelines coming into effect in June).  The other three are being sold at full retail price. 

The three at full price are Blue Diesel - $50 per gram (64% THC level), Rainbow Arc - $80 per gram (67% THC level), and Dosydo - $120 per gram (71% THC level).  It seems like the higher the THC level the more expensive the product. 

On March 22nd LDS put out more news about Reveur. In describing the product they mentioned it having THC levels in the "mid 80s" which would make it the best (and presumably most expensive) live resin available. 

Assuming they price Reveur at the same level of Dosydo - $120 per gram (even though Reveur has at least 10% higher THC concentration) we can start doing some revenue math.

15,000 grams x $120 per gram = 1,800,000.  Give them a gross margin of 50% (basically a 100% markup for the retailer) and you get 900k for LDS. I would consider this the absolute worst case scenario - selling just the amount they've announced for the same price as an inferior competitor. 

Long story short, I expect LDS to announce something like a million dollars in revenue (at a minimum) sometime in the next 3 weeks. If they have produced a lot more product than 15,000 grams that revenue number could be much, much higher. 

 
Bullboard Posts